# Ayesha Biopsy Wednesday - Complete Readiness Checklist

## üéØ Critical Information to Extract

### **From Pathology Report (Baseline):**
1. **Histology Confirmation:**
   - High-grade serous? (most likely)
   - Clear cell? Endometrioid? Mucinous? (less common)
   - Grade (1, 2, 3)

2. **Tumor Markers (if available from biopsy):**
   - CA-125 level (current)
   - HE4 level (if measured)

### **From Tumor Sequencing (Foundation One / Tempus):**

**MUST REQUEST:**
- ‚úÖ Foundation One CDx (most comprehensive for solid tumors)
- ‚úÖ OR Tempus xT (alternative)
- ‚úÖ Ensure they sequence TUMOR tissue, not just germline

**What Will Be Reported:**

#### **1. TP53 Status (96% likelihood it's mutated)**
```
Expected finding: TP53 mutation (missense, nonsense, or frameshift)
Why it matters:
- Confirms high-grade serous histology
- Creates synthetic lethality opportunities:
  ‚Üí WEE1 inhibitors (Adavosertib) - clinical trials
  ‚Üí CHK1 inhibitors (Prexasertib) - clinical trials
  ‚Üí TP53 reactivators (APR-246/Eprenetapopt) - trials
Food/Supplement Impact (A‚ÜíB):
- Vitamin D: Partially restores TP53-like transcriptional programs (VDR-mediated)
- Our Food Validator ALREADY covers this!
```

#### **2. HRD Score (50% likelihood it's positive)**
```
Scoring: 0-100 scale
- ‚â•42 = HRD-positive (PARP inhibitor eligible)
- <42 = HRD-negative (PARP inhibitors less effective)

Expected mutations contributing to HRD:
- Somatic BRCA1/2 mutations (10-15% of cases)
- RAD51C/D mutations
- ATM mutations
- PALB2 mutations
- Or "BRCAness" (epigenetic BRCA inactivation)

If HRD-positive:
‚úÖ Olaparib (FDA-approved for HRD+ ovarian)
‚úÖ Niraparib (FDA-approved)
‚úÖ Rucaparib (FDA-approved)

Food/Supplement Impact (A‚ÜíB):
- Vitamin D: Enhances BRCA1 function, supports HR repair
- Folate/B12: DNA synthesis substrates for remaining repair pathways
- NAC: Supports mitochondrial function under repair stress
```

#### **3. PIK3CA/PTEN/AKT Mutations (35% likelihood)**
```
Expected findings:
- PIK3CA hotspot mutations (E542K, E545K, H1047R, H1047L)
- PTEN loss/inactivation
- AKT amplification

If PIK3CA/PTEN altered:
‚úÖ Alpelisib (PI3K inhibitor) + fulvestrant - clinical trials
‚úÖ Everolimus (mTOR inhibitor) - some evidence
‚úÖ Capivasertib (AKT inhibitor) - trials

Food/Supplement Impact (A‚ÜíB):
- Omega-3: Modulates PI3K/AKT-driven inflammation (NF-Œ∫B)
- Curcumin: Modest PI3K/AKT inhibition (bioavailability barrier!)
- Berberine: Glucose metabolism modulation (supplement, not in our current list)
```

#### **4. TMB/MSI (Low likelihood in ovarian, but check)**
```
TMB (Tumor Mutational Burden):
- High: ‚â•10 mutations/megabase ‚Üí Immunotherapy eligible
- Low: <10 mutations/megabase ‚Üí Immunotherapy unlikely to work

MSI (Microsatellite Instability):
- MSI-H (high): Immunotherapy eligible (pembrolizumab FDA-approved)
- MSS (stable): Standard approach

Ovarian cancer TMB/MSI stats:
- ~5% are MSI-H (usually endometrioid or clear cell)
- ~10% have TMB-high
- Most HGS ovarian are TMB-low, MSS

If TMB-high or MSI-H:
‚úÖ Pembrolizumab (Keytruda) - FDA-approved for MSI-H
‚úÖ Dostarlimab - FDA-approved for MSI-H
‚úÖ Nivolumab + ipilimumab - trials
```

#### **5. Other Somatic Alterations**
```
KRAS/NRAS/BRAF (10-15% of ovarian):
- KRAS G12/G13 mutations
- NRAS Q61 mutations
- BRAF V600E (rare in ovarian, more common in melanoma)

If BRAF V600E:
‚úÖ Dabrafenib + trametinib (MEK inhibitor) - off-label, trials

CCNE1 amplification (20% of HGS):
- Predicts platinum resistance
- No FDA-approved targeted therapy yet
- Trials: WEE1 inhibitors

MYC amplification (30% of HGS):
- Predicts aggressive disease
- No direct targeted therapy
- Trials: BET inhibitors, CDK inhibitors

NF1 loss (10% of HGS):
- Activates RAS/MAPK pathway
- MEK inhibitors (trametinib) - trials
```

---

## üéØ WHAT TO ASK ONCOLOGIST ON WEDNESDAY

### **Before Biopsy:**
1. "Will you be ordering Foundation One CDx or Tempus xT on the tumor tissue?"
   - If NO ‚Üí "Can we request it? Insurance usually covers for Stage III/IV."
2. "How long will tumor sequencing results take?"
   - Expected: 2-3 weeks for Foundation One
3. "Will you also measure CA-125 and HE4?"

### **After Biopsy (Same Day if Possible):**
1. "What histology did the frozen section show?"
   - Confirm: High-grade serous? Other?
2. "When will final pathology report be ready?"
   - Expected: 3-5 days
3. "When will tumor sequencing results be ready?"
   - Expected: 2-3 weeks

### **For Treatment Planning:**
1. "What was my platinum-free interval from Line 1?"
   - (Last carboplatin dose date) ‚Üí (Progression date)
   - If <6 months = platinum-resistant
   - If >6 months = platinum-sensitive
2. "What are my Line 3 treatment options?"
   - Standard options vs. clinical trials
3. "Are there any clinical trials I should consider?"
   - Especially if HRD-positive, PIK3CA-mutant, or TMB-high

---

## üéØ IMMEDIATE PREPARATION (TONIGHT)

### **1. Build Tumor NGS Result Parser (2 hours)**
**What**: Backend endpoint to parse Foundation One JSON/PDF
**Why**: So we can instantly analyze results when they come back
**File**: `oncology-coPilot/oncology-backend-minimal/api/routers/tumor_sequencing.py`
**Integration**: Feeds directly into WIWFM for drug efficacy ranking

### **2. Pre-Compute Drug Recommendations for Each Scenario (1 hour)**
**Scenarios to pre-compute:**
- Scenario A: TP53 mutant + HRD-positive + PIK3CA WT
  - Top drugs: Olaparib, Niraparib, Vitamin D, Omega-3
- Scenario B: TP53 mutant + HRD-negative + PIK3CA mutant
  - Top drugs: Alpelisib trials, Everolimus, Omega-3, Curcumin
- Scenario C: TP53 mutant + HRD-negative + PIK3CA WT
  - Top drugs: WEE1i/CHK1i trials, Vitamin D, Omega-3
- Scenario D: MSI-H or TMB-high
  - Top drugs: Pembrolizumab, Dostarlimab

### **3. Prepare Clinical Trial Search Query (30 min)**
**Pre-build search for:**
- Ovarian cancer + TP53 mutant + HRD-positive
- Ovarian cancer + PIK3CA mutant
- Ovarian cancer + Line 3+
- Ovarian cancer + platinum-resistant

---

## üìã WHAT AYESHA CAN DO NOW (Food Validator)

‚úÖ **Start TODAY (No NGS Required):**
1. **Vitamin D**: 4000 IU daily
   - Rationale: 96% chance she has TP53 mutation (HGS)
   - Mechanism: VDR restores TP53-like programs, enhances BRCA1
2. **Omega-3**: 2-4g EPA+DHA daily
   - Rationale: Post-platinum inflammation (NF-Œ∫B, IL-6)
   - Mechanism: Anti-inflammatory, may resensitize to platinum

‚è≥ **Wait for NGS to Add:**
- If HRD-positive ‚Üí Add NAC (glutathione support)
- If PIK3CA-mutant ‚Üí Emphasize Omega-3 (higher dose)
- If TMB-high ‚Üí Add immune-supportive foods (Vitamin D already covers this)

---

## üî¨ PLATFORM READINESS STATUS

### **‚úÖ READY NOW:**
- Food Validator (disease biology-based A‚ÜíB)
- Treatment line intelligence (L3 post-platinum)
- Provenance tracking

### **‚è≥ BUILD THIS WEEK (Before NGS Results):**
1. Tumor NGS parser (Foundation One/Tempus)
2. Personalized WIWFM (tumor mutation-specific)
3. Clinical trial matcher (mutation-specific)
4. Personalized Food Validator (tumor A‚ÜíB)

### **üéØ READY WHEN NGS ARRIVES:**
- Complete therapeutic strategy report
- Drug efficacy ranking with tumor-specific confidence
- Personalized food/supplement recommendations
- Clinical trial matches (mutation-required trials)

---

## üìä EXPECTED TIMELINE

```
Wednesday (Biopsy Day):
- Confirm tumor sequencing ordered
- Get frozen section histology
- Current CA-125 level

Friday-Monday (3-5 days):
- Final pathology report
- Histology confirmation

Week 2-3 (10-21 days):
- Foundation One results arrive
- INSTANT ANALYSIS via our platform:
  ‚Üí Drug efficacy ranking
  ‚Üí Personalized food recommendations
  ‚Üí Clinical trial matches
  ‚Üí Complete therapeutic strategy

Week 4:
- Oncologist reviews results
- Treatment plan finalized
- Ayesha has our platform-generated report to discuss
```

---

## ‚öîÔ∏è STRATEGIC ADVANTAGE

**What Ayesha Gets That Others Don't:**
1. **Instant Analysis**: Foundation One results ‚Üí Our platform ‚Üí Ranked drugs in <10 seconds
2. **Personalized Food/Supplements**: A‚ÜíB mapping with HER actual tumor mutations
3. **Clinical Trial Matches**: Mutation-specific trials filtered for her profile
4. **Transparent Confidence**: See exactly WHY each recommendation is made

**What Her Oncologist Gets:**
- Evidence-based, mechanism-anchored therapeutic strategy
- Clinical trial options with eligibility pre-checked
- Literature citations for every recommendation
- Provenance tracking (reproducible, auditable)

